Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367

Lin, Min; Kowolik, Claudia M.; Xie, Jun; Yadav, Sushma; Overman, Larry E.; Horne, David A.

doi:10.3390/cancers13246151

Open AccessCorrection

Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367

by

Min Lin

^1,†,

Claudia M. Kowolik

^1,*,†,

Jun Xie

¹,

Sushma Yadav

^1,2

,

Larry E. Overman

³

and

David A. Horne

^1,*

¹

Department of Molecular Medicine, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA

²

Department of Translational Research and Cellular Therapeutics, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA

³

Department of Chemistry, University of California, Irvine, CA 92697-2025, USA

^*

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Cancers 2021, 13(24), 6151; https://doi.org/10.3390/cancers13246151

Submission received: 2 November 2021 / Accepted: 22 November 2021 / Published: 7 December 2021

Download Versions Notes

There is an omission in the Institutional Review Board Statement and Conflict of Interest statements of the paper [1]. The authors would like to update the following parts:

Institutional Review Board Statement: Mouse care and experimental procedures were performed under pathogen-free conditions in accordance with approved protocols from the institutional animal care and use committee of the City of Hope National Medical Center (City of Hope IACUC protocol # is 13053 approved 2 November 2014).

Conflicts of Interest: D.A.H. and L.E.O. are cofounders of Novonco Therapeutics Inc., Los Angeles, CA, USA. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

We apologize for this error and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

Lin, M.; Kowolik, C.M.; Xie, J.; Yadav, S.; Overman, L.E.; Horne, D.A. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367. [Google Scholar] [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Lin, M.; Kowolik, C.M.; Xie, J.; Yadav, S.; Overman, L.E.; Horne, D.A. Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367. Cancers 2021, 13, 6151. https://doi.org/10.3390/cancers13246151

AMA Style

Lin M, Kowolik CM, Xie J, Yadav S, Overman LE, Horne DA. Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367. Cancers. 2021; 13(24):6151. https://doi.org/10.3390/cancers13246151

Chicago/Turabian Style

Lin, Min, Claudia M. Kowolik, Jun Xie, Sushma Yadav, Larry E. Overman, and David A. Horne. 2021. "Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367" Cancers 13, no. 24: 6151. https://doi.org/10.3390/cancers13246151

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Lin et al. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers 2021, 13, 3367

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI